Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib-Reference-Cited by-同舟云学术

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

Published:2020-06-27 Issue:12 Volume:60 Page:1617-1628
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Tse Susanna¹,Dowty Martin E.²,Menon Sujatha³,Gupta Pankaj⁴,Krishnaswami Sriram⁵

Affiliation:

1. Department of Pharmacokinetics Dynamics, and Metabolism, Pfizer Inc. Groton Connecticut USA

2. Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc. Cambridge Massachusetts USA

3. Department of Clinical Pharmacology, Pfizer Inc. Groton Connecticut USA

4. Worldwide Business Development, Pfizer Inc. New York New York USA

5. Global Product Development, Pfizer Inc. Groton Connecticut USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1679

Reference33 articles.

1. Clinicaltrials.gov.A safety efficacy and pharmacokinetics study of tofacitinib in pediatric patients with sJIA.https://clinicaltrials.gov/ct2/show/NCT03000439. Accessed February 11 2020.

2. Clinicaltrials.gov.Efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis (AS).https://clinicaltrials.gov/ct2/show/NCT03502616. Accessed February 7 2020.

3. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

4. The mechanism of action of tofacitinib ‐ an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis;Hodge JA;Clin Exp Rheumatol,2016

5. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations;AAPS PharmSciTech;2024-05-28

2. Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form;Clinical Pharmacology & Therapeutics;2024-05-26

3. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study;Clinical and Experimental Medicine;2024-05-10

4. Approaches of formulation bridging in support of orally administered drug product development;International Journal of Pharmaceutics;2022-12

5. A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling;British Journal of Clinical Pharmacology;2022-06-16